Mano Horinaka
Overview
Explore the profile of Mano Horinaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki T, Eitoku M, Kitamura Y, Takeda M, Mori N, Maruyama S, et al.
Nihon Eiseigaku Zasshi
. 2025 Feb;
80.
PMID: 39971317
Hygiene is a field of study that aims to "protect health" and "protect lifestyle" of people from external factors such as bacteria, poor nutrition, and toxic chemicals, as well as...
2.
Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682244
Background: Histone deacetylase (HDAC) inhibitors have been reported to exhibit immunomodulatory activities, including the upregulation of major histocompatibility complex class I (MHC class I). Although the immunoproteasome plays a pivotal...
3.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, et al.
Clin Cancer Res
. 2024 Nov;
PMID: 39495173
Purpose: Rearranged during transfection (RET) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients with RET-aberrant cancer are insensitive to RET...
4.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al.
Cancer Lett
. 2024 Jul;
598:217124.
PMID: 39059573
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in...
5.
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, et al.
Cancer Sci
. 2024 Jul;
115(10):3333-3345.
PMID: 39039802
Lazertinib, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), demonstrates marked efficacy in EGFR-mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome...
6.
Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T, et al.
Br J Cancer
. 2024 May;
131(2):361-371.
PMID: 38822146
Background: Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK pathway have attracted considerable attention. The RAF/MEK clamp avutometinib (VS-6766/CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib...
7.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, et al.
Cancer Lett
. 2024 Feb;
587:216692.
PMID: 38342232
Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is...
8.
Ota Y, Itoh Y, Takada Y, Yamashita Y, Hu C, Horinaka M, et al.
Bioorg Med Chem
. 2024 Feb;
100():117632.
PMID: 38340642
Small molecule-based selective cancer cell-targeting can be a desirable anticancer therapeutic strategy. Aiming to discover such small molecules, we previously developed phenylcyclopropylamine (PCPA)-drug conjugates (PDCs) that selectively release anticancer agents...
9.
Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, et al.
Mol Cancer Ther
. 2023 Oct;
23(2):212-222.
PMID: 37802502
Few treatment options exist for pleural mesothelioma (PM), which is a progressive malignant tumor. However, the efficacy of molecular-targeted monotherapy is limited, and further therapeutic strategies are warranted to treat...
10.
Masuda M, Horinaka M, Yasuda S, Morita M, Nishimoto E, Ishikawa H, et al.
Environ Health Prev Med
. 2023 Sep;
28:54.
PMID: 37743524
Background: Recent advances have been achieved in the genetic diagnosis and therapies against malignancies due to a better understanding of the molecular mechanisms underlying carcinogenesis. Since active preventive methods are...